Study wrapper · #674
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
Editor's note
In a female-mouse spinal-cord-injury model, researchers reported that Semax improved functional recovery scores and reduced markers of lysosomal-membrane-permeabilization-driven cell death, and used RNA-seq, network pharmacology and molecular docking to nominate the mu-opioid receptor and the deubiquitinase USP18 as mediators. It is a mechanistically ambitious single preclinical study; the causal chain (mu-opioid to USP18 to FTO deubiquitination) rests partly on knockdown and in-silico docking rather than definitive pharmacology. Findings are directionally consistent with Semax's broader anti-inflammatory and neuroprotective rodent literature but remain preclinical, and the model used only female mice, limiting generalization. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
After a spinal cord injury, nerve cells can die partly because tiny cellular 'recycling bins' (lysosomes) leak. This study, in female mice, tested whether the peptide Semax could reduce that damage and aid recovery. Mice with spinal cord injuries that received Semax walked better on standardized tests and showed fewer signs of this leak-driven cell death. Using gene-activity analysis and computer modeling, the researchers traced a possible pathway: Semax appears to act on the mu-opioid receptor, which influences a protein called USP18 and, in turn, tags another protein (FTO). Lowering USP18 experimentally confirmed its role. The authors suggest Semax has potential for spinal cord injury. Because this was done only in female mice and relies partly on computer predictions, it identifies a possible mechanism rather than a proven human benefit, and no side-effect data are reported.